Current trends in small cell lung cancer management—ASCO 2019 update
- 3 Downloads
During the last 30 years the developments in small cell lung cancer (SCLC) have been extremely scarce. Concurrent chemo-radiation associated with prophylactic cranial irradiation in case of complete clinical remission is standard in limited disease. In extensive disease, platinum/etoposide and topotecan remain the standard systemic approaches in the first- and second-line setting, respectively. The only notable improvement was communicated in the IMpower133 trial, by the addition of atezolizumab to the platinum/etoposide chemotherapy backbone. Against this background, the current article aims to review the most important abstracts presented at ASCO 2019 along with their potential impact for current clinical practice.
KeywordsSCLC Management ASCO 2019
Conflict of interest
M. Dediu served as consultant and received speaker honoraria from: Boehringer-Ingelheim, Roche, Novartis, MSD, Astra-Zeneca, Bristol-Myers Squibb, Ipsen, Sandoz, Pfizer, Astellas, Merck.
- 4.NCCN guidelines version 2.2019. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf
- 6.Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol. 1997;15(5):2090–6.CrossRefGoogle Scholar
- 9.Reck M, Vicente D, Ciuleanu T, Gettinger S, Peters S, Horn LReck M, et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331. Ann Oncol. 2018;29(suppl_10):x39–x43. https://doi.org/10.1093/annonc/mdy511.CrossRefGoogle Scholar
- 10.Paz-Ares L, Perez J, Besse B, Moreno V, Lopez R, Sala, et al. Efficacy and safety profile of lurbinectedin in second-line SCLC patients: Results from a phase II single-agent trial. J Clin Oncol. 2019;37(suppl):abstr 8506.Google Scholar
- 12.Hart L, Andric Z, Hussein M, Ferrarotto R, Beck T, Subramanian J, et al. Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. J Clin Oncol. 2019;37(suppl):abstr 8505.Google Scholar
- 14.Owonikoko T, Higgins K, Chen Z, Zhang C, Pillai R, Steuer CE, et al. A randomized phase II study of tremelimumab and durvalumab with or without radiation for patients with relapsed small cell lung cancer (SCLC). J Clin Oncol. 2019;37(suppl):abstr 8515.Google Scholar
- 15.Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel J, et al. Ph1/2 study of Rova‑T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC. J Clin Oncol. 2019;37(suppl):abstr 8516.Google Scholar
- 16.Carbone D, Morgensztern D, Le Moulec S, Santana-Davila R, Ready N, Hann C, et al. Efficacy and safety of rovalpituzumab tesirine (Rova-TTM) in patients with DLL3-expressing, ≥3rd line small cell lung cancer: results from the phase 2 TRINITY study. J Clin Oncol. 2018;36(suppl):abstr 8507.CrossRefGoogle Scholar
- 18.Park S, Shim J, Jung H, Sun JM, Lee SH, Park WY, et al. Biomarker driven phase II umbrella trial study of AZD1775, AZD2014, AZD2811 monotherapy in relapsed small cell lung cancer. J Clin Oncol. 2019;37(suppl):abstr 8514.Google Scholar
- 19.Owonikoko TK, Kim HR, Govindan R, Ready N, M. Reck M, Peters S, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study. Presented at: 2019 European Lung Cancer Congress; April 11 to 13, 2019; Geneva, Switzerland. Abstract LBA1.Google Scholar
- 21.Phase 3 Trial of Rova‑T as Second-line Therapy for Advanced Small-Cell Lung Cancer (TAHOE Study) Halted. AbbVie. Published December 5, 2018. https://bit.ly/2KZcyVl. Accessed December 6, 2018.